Whole glucan particles as a vaccine against systemic coccidioidomycosis
We reported previously that yeast-derived whole glucan particles (WGPs), with or without conjugation to BSA, used as a vaccine protected against systemic aspergillosis in mice. Here, we examined their utility as a potential vaccine against coccidioidomycosis. WGPs were prepared from Saccharomyces ce...
Gespeichert in:
| Veröffentlicht in: | Journal of medical microbiology 2015-10, Vol.64 (10), p.1237-1243 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1243 |
|---|---|
| container_issue | 10 |
| container_start_page | 1237 |
| container_title | Journal of medical microbiology |
| container_volume | 64 |
| creator | Clemons, Karl V Antonysamy, Mary A Danielson, Michael E Michel, Kyle S Martinez, Marife Chen, Vicky Stevens, David A |
| description | We reported previously that yeast-derived whole glucan particles (WGPs), with or without conjugation to BSA, used as a vaccine protected against systemic aspergillosis in mice. Here, we examined their utility as a potential vaccine against coccidioidomycosis. WGPs were prepared from Saccharomyces cerevisiae; conjugation with BSA (WGP-BSA) was done using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate-mediated conjugation. Heat-killed S. cerevisiae (HKY) was used as a positive-control vaccine. CD-1 mice were vaccinated with WGPs or WGP-BSA, HKY or PBS once weekly, beginning 21 days prior to infection. Mice were infected intravenously with arthroconidia of Coccidioides posadasii. In the low-mortality study, 50 % of PBS-treated controls died. Only WGP-BSA at 0.6 mg per dose induced significant protection compared with PBS treatment. All surviving mice were infected in all three organs examined. Those given WGP-BSA at 0.6 mg per dose had fewer c.f.u. in liver and lungs (P = 0.04), and those given WGPs at 6 mg per dose had fewer in lungs (P |
| doi_str_mv | 10.1099/jmm.0.000138 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1722930242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1722930242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-50b47b2ebd946873a7fc221b840a0dcb65499398b7e9c63be9d2cbf3b550d1053</originalsourceid><addsrcrecordid>eNo9kMFLwzAYxYMobk5vnqVHD7Z--ZI2zVGGTmHgRfEYkjSdGW0zm1bYf29lU3jwDu_HO_wIuaaQUZDyftu2GWQAQFl5QuaUC5bmBeenZA6AmGJB8xm5iHE7IYIxeU5mWKAUFMWcrD4-Q-OSTTNa3SU73Q_eNi4mekryra31nUv0RvsuDkncx8G13iY2TEPlg69Cu7ch-nhJzmrdRHd17AV5f3p8Wz6n69fVy_JhnVqGckhzMFwYdKaSvCgF06K2iNSUHDRU1hQ5l5LJ0ggnbcGMkxVaUzOT51BRyNmC3B5-d334Gl0cVOujdU2jOxfGqKhAlAyQ44TeHVDbhxh7V6td71vd7xUF9atOTeoUqIO6Cb85Po-mddU__OeK_QA33Wnv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1722930242</pqid></control><display><type>article</type><title>Whole glucan particles as a vaccine against systemic coccidioidomycosis</title><source>MEDLINE</source><source>Microbiology Society</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Clemons, Karl V ; Antonysamy, Mary A ; Danielson, Michael E ; Michel, Kyle S ; Martinez, Marife ; Chen, Vicky ; Stevens, David A</creator><creatorcontrib>Clemons, Karl V ; Antonysamy, Mary A ; Danielson, Michael E ; Michel, Kyle S ; Martinez, Marife ; Chen, Vicky ; Stevens, David A</creatorcontrib><description>We reported previously that yeast-derived whole glucan particles (WGPs), with or without conjugation to BSA, used as a vaccine protected against systemic aspergillosis in mice. Here, we examined their utility as a potential vaccine against coccidioidomycosis. WGPs were prepared from Saccharomyces cerevisiae; conjugation with BSA (WGP-BSA) was done using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate-mediated conjugation. Heat-killed S. cerevisiae (HKY) was used as a positive-control vaccine. CD-1 mice were vaccinated with WGPs or WGP-BSA, HKY or PBS once weekly, beginning 21 days prior to infection. Mice were infected intravenously with arthroconidia of Coccidioides posadasii. In the low-mortality study, 50 % of PBS-treated controls died. Only WGP-BSA at 0.6 mg per dose induced significant protection compared with PBS treatment. All surviving mice were infected in all three organs examined. Those given WGP-BSA at 0.6 mg per dose had fewer c.f.u. in liver and lungs (P = 0.04), and those given WGPs at 6 mg per dose had fewer in lungs (P < 0.02), compared with PBS. In the high-mortality study, 90 % of PBS mice died. Vaccination with HKY, and WGPs or WGP-BSA at 6 or 12 mg per dose significantly prolonged survival (P ≤ 0.05). No surviving mice were free of infection. HKY and WGP-BSA at 12 mg per dose reduced c.f.u. in the liver and lungs (P < 0.05) and WGP-BSA at 6 mg per dose reduced c.f.u. in the lungs (P < 0.05); unconjugated WGPs did not reduce infection. WGPs or WGP-BSA acted as a vaccine that protected against mortality caused by coccidioidomycosis. Thus, WGP protection against coccidioidomycosis and aspergillosis provides the basis for development of a pan-fungal vaccine.</description><identifier>ISSN: 0022-2615</identifier><identifier>EISSN: 1473-5644</identifier><identifier>DOI: 10.1099/jmm.0.000138</identifier><identifier>PMID: 26297127</identifier><language>eng</language><publisher>England</publisher><subject><![CDATA[Animal Structures - microbiology ; Animals ; Coccidioides - immunology ; Coccidioidomycosis - immunology ; Coccidioidomycosis - prevention & control ; Colony Count, Microbial ; Disease Models, Animal ; Fungal Vaccines - administration & dosage ; Fungal Vaccines - immunology ; Fungal Vaccines - isolation & purification ; Glucans - administration & dosage ; Glucans - immunology ; Glucans - isolation & purification ; Male ; Mice ; Saccharomyces cerevisiae - chemistry ; Serum Albumin, Bovine - administration & dosage ; Survival Analysis ; Vaccines, Conjugate - administration & dosage ; Vaccines, Conjugate - immunology ; Vaccines, Conjugate - isolation & purification]]></subject><ispartof>Journal of medical microbiology, 2015-10, Vol.64 (10), p.1237-1243</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-50b47b2ebd946873a7fc221b840a0dcb65499398b7e9c63be9d2cbf3b550d1053</citedby><cites>FETCH-LOGICAL-c329t-50b47b2ebd946873a7fc221b840a0dcb65499398b7e9c63be9d2cbf3b550d1053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3733,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26297127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Clemons, Karl V</creatorcontrib><creatorcontrib>Antonysamy, Mary A</creatorcontrib><creatorcontrib>Danielson, Michael E</creatorcontrib><creatorcontrib>Michel, Kyle S</creatorcontrib><creatorcontrib>Martinez, Marife</creatorcontrib><creatorcontrib>Chen, Vicky</creatorcontrib><creatorcontrib>Stevens, David A</creatorcontrib><title>Whole glucan particles as a vaccine against systemic coccidioidomycosis</title><title>Journal of medical microbiology</title><addtitle>J Med Microbiol</addtitle><description>We reported previously that yeast-derived whole glucan particles (WGPs), with or without conjugation to BSA, used as a vaccine protected against systemic aspergillosis in mice. Here, we examined their utility as a potential vaccine against coccidioidomycosis. WGPs were prepared from Saccharomyces cerevisiae; conjugation with BSA (WGP-BSA) was done using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate-mediated conjugation. Heat-killed S. cerevisiae (HKY) was used as a positive-control vaccine. CD-1 mice were vaccinated with WGPs or WGP-BSA, HKY or PBS once weekly, beginning 21 days prior to infection. Mice were infected intravenously with arthroconidia of Coccidioides posadasii. In the low-mortality study, 50 % of PBS-treated controls died. Only WGP-BSA at 0.6 mg per dose induced significant protection compared with PBS treatment. All surviving mice were infected in all three organs examined. Those given WGP-BSA at 0.6 mg per dose had fewer c.f.u. in liver and lungs (P = 0.04), and those given WGPs at 6 mg per dose had fewer in lungs (P < 0.02), compared with PBS. In the high-mortality study, 90 % of PBS mice died. Vaccination with HKY, and WGPs or WGP-BSA at 6 or 12 mg per dose significantly prolonged survival (P ≤ 0.05). No surviving mice were free of infection. HKY and WGP-BSA at 12 mg per dose reduced c.f.u. in the liver and lungs (P < 0.05) and WGP-BSA at 6 mg per dose reduced c.f.u. in the lungs (P < 0.05); unconjugated WGPs did not reduce infection. WGPs or WGP-BSA acted as a vaccine that protected against mortality caused by coccidioidomycosis. Thus, WGP protection against coccidioidomycosis and aspergillosis provides the basis for development of a pan-fungal vaccine.</description><subject>Animal Structures - microbiology</subject><subject>Animals</subject><subject>Coccidioides - immunology</subject><subject>Coccidioidomycosis - immunology</subject><subject>Coccidioidomycosis - prevention & control</subject><subject>Colony Count, Microbial</subject><subject>Disease Models, Animal</subject><subject>Fungal Vaccines - administration & dosage</subject><subject>Fungal Vaccines - immunology</subject><subject>Fungal Vaccines - isolation & purification</subject><subject>Glucans - administration & dosage</subject><subject>Glucans - immunology</subject><subject>Glucans - isolation & purification</subject><subject>Male</subject><subject>Mice</subject><subject>Saccharomyces cerevisiae - chemistry</subject><subject>Serum Albumin, Bovine - administration & dosage</subject><subject>Survival Analysis</subject><subject>Vaccines, Conjugate - administration & dosage</subject><subject>Vaccines, Conjugate - immunology</subject><subject>Vaccines, Conjugate - isolation & purification</subject><issn>0022-2615</issn><issn>1473-5644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMFLwzAYxYMobk5vnqVHD7Z--ZI2zVGGTmHgRfEYkjSdGW0zm1bYf29lU3jwDu_HO_wIuaaQUZDyftu2GWQAQFl5QuaUC5bmBeenZA6AmGJB8xm5iHE7IYIxeU5mWKAUFMWcrD4-Q-OSTTNa3SU73Q_eNi4mekryra31nUv0RvsuDkncx8G13iY2TEPlg69Cu7ch-nhJzmrdRHd17AV5f3p8Wz6n69fVy_JhnVqGckhzMFwYdKaSvCgF06K2iNSUHDRU1hQ5l5LJ0ggnbcGMkxVaUzOT51BRyNmC3B5-d334Gl0cVOujdU2jOxfGqKhAlAyQ44TeHVDbhxh7V6td71vd7xUF9atOTeoUqIO6Cb85Po-mddU__OeK_QA33Wnv</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Clemons, Karl V</creator><creator>Antonysamy, Mary A</creator><creator>Danielson, Michael E</creator><creator>Michel, Kyle S</creator><creator>Martinez, Marife</creator><creator>Chen, Vicky</creator><creator>Stevens, David A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Whole glucan particles as a vaccine against systemic coccidioidomycosis</title><author>Clemons, Karl V ; Antonysamy, Mary A ; Danielson, Michael E ; Michel, Kyle S ; Martinez, Marife ; Chen, Vicky ; Stevens, David A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-50b47b2ebd946873a7fc221b840a0dcb65499398b7e9c63be9d2cbf3b550d1053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animal Structures - microbiology</topic><topic>Animals</topic><topic>Coccidioides - immunology</topic><topic>Coccidioidomycosis - immunology</topic><topic>Coccidioidomycosis - prevention & control</topic><topic>Colony Count, Microbial</topic><topic>Disease Models, Animal</topic><topic>Fungal Vaccines - administration & dosage</topic><topic>Fungal Vaccines - immunology</topic><topic>Fungal Vaccines - isolation & purification</topic><topic>Glucans - administration & dosage</topic><topic>Glucans - immunology</topic><topic>Glucans - isolation & purification</topic><topic>Male</topic><topic>Mice</topic><topic>Saccharomyces cerevisiae - chemistry</topic><topic>Serum Albumin, Bovine - administration & dosage</topic><topic>Survival Analysis</topic><topic>Vaccines, Conjugate - administration & dosage</topic><topic>Vaccines, Conjugate - immunology</topic><topic>Vaccines, Conjugate - isolation & purification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Clemons, Karl V</creatorcontrib><creatorcontrib>Antonysamy, Mary A</creatorcontrib><creatorcontrib>Danielson, Michael E</creatorcontrib><creatorcontrib>Michel, Kyle S</creatorcontrib><creatorcontrib>Martinez, Marife</creatorcontrib><creatorcontrib>Chen, Vicky</creatorcontrib><creatorcontrib>Stevens, David A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Clemons, Karl V</au><au>Antonysamy, Mary A</au><au>Danielson, Michael E</au><au>Michel, Kyle S</au><au>Martinez, Marife</au><au>Chen, Vicky</au><au>Stevens, David A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Whole glucan particles as a vaccine against systemic coccidioidomycosis</atitle><jtitle>Journal of medical microbiology</jtitle><addtitle>J Med Microbiol</addtitle><date>2015-10</date><risdate>2015</risdate><volume>64</volume><issue>10</issue><spage>1237</spage><epage>1243</epage><pages>1237-1243</pages><issn>0022-2615</issn><eissn>1473-5644</eissn><abstract>We reported previously that yeast-derived whole glucan particles (WGPs), with or without conjugation to BSA, used as a vaccine protected against systemic aspergillosis in mice. Here, we examined their utility as a potential vaccine against coccidioidomycosis. WGPs were prepared from Saccharomyces cerevisiae; conjugation with BSA (WGP-BSA) was done using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate-mediated conjugation. Heat-killed S. cerevisiae (HKY) was used as a positive-control vaccine. CD-1 mice were vaccinated with WGPs or WGP-BSA, HKY or PBS once weekly, beginning 21 days prior to infection. Mice were infected intravenously with arthroconidia of Coccidioides posadasii. In the low-mortality study, 50 % of PBS-treated controls died. Only WGP-BSA at 0.6 mg per dose induced significant protection compared with PBS treatment. All surviving mice were infected in all three organs examined. Those given WGP-BSA at 0.6 mg per dose had fewer c.f.u. in liver and lungs (P = 0.04), and those given WGPs at 6 mg per dose had fewer in lungs (P < 0.02), compared with PBS. In the high-mortality study, 90 % of PBS mice died. Vaccination with HKY, and WGPs or WGP-BSA at 6 or 12 mg per dose significantly prolonged survival (P ≤ 0.05). No surviving mice were free of infection. HKY and WGP-BSA at 12 mg per dose reduced c.f.u. in the liver and lungs (P < 0.05) and WGP-BSA at 6 mg per dose reduced c.f.u. in the lungs (P < 0.05); unconjugated WGPs did not reduce infection. WGPs or WGP-BSA acted as a vaccine that protected against mortality caused by coccidioidomycosis. Thus, WGP protection against coccidioidomycosis and aspergillosis provides the basis for development of a pan-fungal vaccine.</abstract><cop>England</cop><pmid>26297127</pmid><doi>10.1099/jmm.0.000138</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2615 |
| ispartof | Journal of medical microbiology, 2015-10, Vol.64 (10), p.1237-1243 |
| issn | 0022-2615 1473-5644 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1722930242 |
| source | MEDLINE; Microbiology Society; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Animal Structures - microbiology Animals Coccidioides - immunology Coccidioidomycosis - immunology Coccidioidomycosis - prevention & control Colony Count, Microbial Disease Models, Animal Fungal Vaccines - administration & dosage Fungal Vaccines - immunology Fungal Vaccines - isolation & purification Glucans - administration & dosage Glucans - immunology Glucans - isolation & purification Male Mice Saccharomyces cerevisiae - chemistry Serum Albumin, Bovine - administration & dosage Survival Analysis Vaccines, Conjugate - administration & dosage Vaccines, Conjugate - immunology Vaccines, Conjugate - isolation & purification |
| title | Whole glucan particles as a vaccine against systemic coccidioidomycosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A57%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Whole%20glucan%20particles%20as%20a%20vaccine%20against%20systemic%20coccidioidomycosis&rft.jtitle=Journal%20of%20medical%20microbiology&rft.au=Clemons,%20Karl%20V&rft.date=2015-10&rft.volume=64&rft.issue=10&rft.spage=1237&rft.epage=1243&rft.pages=1237-1243&rft.issn=0022-2615&rft.eissn=1473-5644&rft_id=info:doi/10.1099/jmm.0.000138&rft_dat=%3Cproquest_cross%3E1722930242%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1722930242&rft_id=info:pmid/26297127&rfr_iscdi=true |